The Role of Depression in Coronary Artery Disease

Arquivos Brasileiros de Cardiologia

Volumn 73, Issue 2, 1999, Pages 244-250

  Luiz Langer Manica, André ^a   Garcia Soares Leães, Carolina ^a   Frey, Benício Noronha ^a   Juruena, Mário Francisco ^a,b  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; HEART RATE VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR;

DEPRESSION; HUMANS; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS;

EID: 0033369983     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Classificação de Transtornos Mentais e de Comportamento da CID-10. Diretrizes Diagnósticas e de Tratamento para Transtornos Mentais em Cuidados Primários. Organização Mundial de Saúde. Porto Alegre: Artes Médicas, 1998: 34.
2. th ed. : , 1994.
3. Kessler RC, McConagle KA, Zhao S, et al. Lifetime and 12-months prevalence of DSM III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
4. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267: 1478-83.
5. Barefoot JC, Schroll M. Symptoms of depression, acute mycardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-80.
6. Aromaa A, Raitasalo R, Reunanen A, et al. Depression and cardiovascular diseases. Acta Psychiatr Scand 1994; 377: 77-82.
7. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270: 1819-24.
8. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999-1005.
9. Ahern DK, Gorkin L, Anderson JL, et al. Biobehavioural variables and mortality or cardiac arrest in the cardiac arrhythmia pilot study (CAPS). Am J Cardiol 1990; 66: 59-62.
10. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of isquemic heart disease in a cohort of us adults. Epidemiology 1993; 4: 285-99.
11. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication and risk of myocardial infarction: prospective data from the Baltimore ECA follow up. Circulation 1996; 94: 3123-9.
12. Ford DE, Mead LA, Chang PP, et al. Depression predicts cardiovascular disease in men: the precursors study. Circulation 1994; 90(suppl I): 614.
13. Hippisley-Cox J, Fielding K, Pringle M. Depression as risk factor for ischaemic heart disease in men: population based case-control study. Br Med J 1998; 316: 1714-9.
14. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785-9.
15. Garrity TF, Klein RF. Emotional response and clinical severity as early determinants of 6-months mortality after myocardial infarction. Heart Lung 1975; 4: 730-7.
16. Carney RM, Freedland KE, Jaffe AS. Insomnia and depression prior to myocardial infarction. Psychosom Med 1990; 52: 603-9.
17. Carney RM, Rich MW, te Velde A, Saini J, Clark K, Jaffe AS. Major depressive disorder in coronary artery disease. Am J Cardiol 1987; 60: 1273-5.
18. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627-33.
19. Hance M, Carney RM, Freedland KE, Skala J. Depression in patients with coronary heart disease: a 12-month follow-up. Gen Hosp Psychiatry 1996; 18: 61-5.
20. Case RB, Moss AJ, Case N, Mcdermott M, Eberly S. Living alone after myocardial infarction: impact on prognosis. JAMA 1992; 267: 515-9.
21. Masthews KA. Are sociodemographic varables markers for psychological determinants of health? Health Psychol 1989; 8: 641-8.
22. Falgar P, Appels A. Psychological risk factors over the life course of myocardial infarction patients. Adv Cardiol 1982; 29: 132-9.
23. Follick MJ, Gorkin L, Capone RJ, et al. Psychological distress as a predictor of ventricular arrhythmias in a post-myocardial infarction population. Am Heart J 1988; 116: 32-6.
24. Ladwig KW, Kieser M, Konig J, et al. Affective disorders and survival after acute myocardial infarction: results from the post-infarction late potential study. Eur Heart J 1991; 12: 959-64.
25. Stern MJ, Pascale L, Ackerman A. Life adjustment post-myocardial infarction: determining predictive varibles. Arch Intern Med 1977; 137: 1680-5.
26. Dwight MM, Stoudemire A. Effects of depressive disorders on coronary artery disease: A review. Harvard Ver Psychiatry 1997; 5: 115-22.
27. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. In-hospital and 1-year mortality in 1524 women after myocardial infarction: comparison with 4315 men. Circulation . 991; 83: 484-91.
28. Carney RM, Freedland KE, Smith LJ, Lustman PJ, Jaffe AS. Relation of depression and mortality after myocardial infarction in women. Circulation 1991; 84: 1876-7.
29. Nutt D. Management of patients with depression associated with anxiety symptoms. J Clin Psychiatry 1997; 58: 11-6.
30. Croog SW, Levine S. Life After Heart Attack. New York: Human Sciences Press, 1982: 33p.
31. Carney RM, Freedland KE, Rich MW, Smith LJ, Jaffe AS. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 1993; 95: 23-8.
32. Musselman DL, Tomer A, Manatunga AK et al. Exagerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 1313-7.
33. Laghrissi-Thode F, Wagner WR, Pollock BJ, Johnson PC, Finkel MS. Elevated platelet factor 4 and b-thromboglobulin plasma levels in depressed patients with isquemic heart disease. Biol Psychiatry 1997; 42: 290-5.
34. Weyrich AS, Solis G A, Li KS, Tulenko TN, Santamore WP, Platelet amplification of vasoespasm. Am J Physiol 1992; 263: H349-H358.
35. DeClerck F. Effects of serotonin on platelet and blood vessels. J Cardiovasc Pharmacol 1991; 17: S1-S5.
36. Biegon A, Weizman A, Karp L, Ram A, Iano S, Wolff M. Serotonin5-HT2 Receptor binding on blood platelets: A periferal marker for depression? Life Sci 1987; 41: 2485-92.
37. Biegon A, Grinspoon A, Blumenfelt B, Bleish A, Apter A, Mester R. Increased serotonin 5-ht2 receptor binding on blood platelets in suicidal men. Psychopharm 1990; 100: 165-7.
38. Biegon A, Essar N, Israeli M, Elizur A, Bruch S, Bar-Natan AA. Serotonin 5-HT2 receptor binding on blood platelets as a state dependent marker in major affective disorder. Psychopharm 1990; 100: 73-5.
39. Arora RC, Meltzer HY. Increased serotonin (5-HT2) receptor binding as measured by 3H-LSD in the blood platelet of depressive patients. Life Sci 1989; 44: 725-34.
40. Pandey GN, Pandey SC, Janicak PG. Platelet serotonin-2 binding sites in depression and suicide. Biol Psychiatry 1990; 28: 215-22.
41. Nemeroff CB, Knight DL, Franks J, Craighead WF, Krishnan KRR. Further studies on platelet serotonin transporter binding in depression. Am J Psychiatry 1994; 151: 1623-5.
42. Owens MJ, Nemeroff CB. Role of serotonin in the patophysiology of depression: Focus on the serotonin transporter. Clin Chem 1994; 40: 288-95.
43. Briley MS, Larger SZ, Raisman R, Sechter D, Zarifian E. Tritiated mipramine binding sites are decreased in platelets of untreated depressed patients. Science 1980; 209: 301-15.
44. Langer SZ, Arifian E, Briley MS, Raisman R, Sechter D. High-affinity binding of 3H-imipramine in brain and platelets and its relevance to the biochemistry of affective disorders. Life Sci 1981; 29: 211-8.
45. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of titrated imipramine to platelet serotonin transporter. Arch Gen Psychiatry 1981; 38: 1315-7.
46. Nemeroff CB, Knight DL, Krishnan KRR, et al. Marked reduction in the number of platelet 3H-imipramine binding sites in geriatric depression. Arch Gen Psychiatry 1988; 45: 919-23.
47. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Eng J Med 1976; 294: 1165-70.
48. Schwartz PJ, Shebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol 1976; 37: 1034-40.
49. Kirby DA, Pinto JMB, Hottinger S, Johnson DA, Lown B. Behavioural arousal enhaces inducibility and rate of ventricular tachycardia. Am J Physiol 1991; 261: H1734-9
50. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM. The relationship among ventricular arrythmias, left ventricular dysfunction, and mortality in 2-years after myocardial infarction. Circulation 1984; 69: 250-8.
51. Roose SP, Dalack GW, Woodring S. Death, depression and heart disease. J Clin Psychiatry 1991; 52: 34-9.
52. Kennedy GJ, Hofer MA, Cohen D, Shindledecker MA, Fisher JD. Significance of depression and cognitive impairment in patients undergoing programmed stimulation of cardiac arrythmias. Psychosom Med 1987; 49: 410-21.
53. Lake CR, Pickar D, Ziegler MG, Lipper S, Slater S, Murphy DL. High plasma norepinephrine levels in patients with major affective disorder. Am J Psychiatry 1982; 39: 295-300.
54. Roy A, Pickar D, Dejong J, Karoun F, Linnoila M. Norepinephrine ans its metabolites in cerebrospinal fluid, plasma, and urine: relationship to hypothalamic-pituitary-adrenal axis function in depression. Arch Gen Psychiatry 1988; 45: 849-57.
55. Veith RC, Lewis L, Linares AO, et al. Sympathetic nervous system activity in major depression: basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51: 411-22.
56. Roy A, Pickar D, Linnoila M, Potter WZ. Plasma norepinephrine level in affective disorders: relationship to melancholia. Arch Gen Psychiatry 1985; 42: 1181-5.
57. Malzberg B. Mortality among patients with involution melancholia. Am J Psychiatry 1937; 93: 1231-8.
58. Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990; 51 (suppl 7): 4-9.
59. Rechlin T, Weis M, Aspitzer A, Kaschka H. Are affective disorders associated with alterations of heart rate variability? J Affect Disord 1994; 32: 271-5.
60. Kleiger, RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 99: 256-62.
61. Carney RM, Saunders RD, Freedland KE, et al. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562-4.
62. Magid NM, Eckberg KL, Sprenkle JM. Low dose atropine reduces ventricular vulnerability in normal and ischemic hearts. J Clin Invest 1983; 31: 261-4.
63. Banki CM, Karmasci L, Bissette G, et al. CSF corticotropin-releasing and somatostatin in major depression: response to antidepressant treatment and relapse. Eur Neuropsycopharmacol 1992; 2: 107-13.
64. Risch SC, Lewine RJ, Kalin NH, et al. Limbic-hypothalamic-pituitary-adrenal axis activity and ventricular-to-brain rature studies in affective illness and schizophrenia. Neuropsycopharmacology 1992; 6: 95-100.
65. Gold PW, Loriaux DL, Roy A, et al. Response to corticotropin-releasing hormone in the hypercorticolism of depression and cushing's disease: pathophysiologic and diagnostic implications. N Engl J Med 1986; 314: 1329-35.
66. Amsterdam JD, Maislin G, Winokur A, et al. Pituitary and adrenocortical response to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers. Arch Gen Psychiatry 1987; 44: 775-81.
67. Charlton BG, Ferner IN. Hypothalamo-pituitary-adrenal axis abnormalities in depression: a review and a model. Psychol Med 1989; 19: 331-6.
68. Amsterdam JD, Winokur A, Abelman E, et al. Cosyntropin stimulation test in depressed patients and healthy controls. Am J Psychiatry 1983; 140: 907-9.
69. Carrol BJ, Martin FI, Davis BM. Resistance to Supression by Dexamethasone of Plasma 11 (OH)CS Levels in Severe Depressive Illness. BMJ 1968; 3: 285-7.
70. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone supression test for diagnosis and prognosis in psychiatry: coommentary and review. Arch Gen Psychiatry 1985; 42: 1193-1204.
71. Arana GW, Mossman D. The desamethasone supression test and depression. Endocrinol Metab Clin North Am 1988; 17: 21-39.
72. Roy A, Guthrie S, Pickar D, Linnoila M. Plasma NE responses to cold challenge in depressed patients and normal controls. Psychiatry Res 1987; 21: 161-8.
73. Thompson DR, Meddis R. A Prospective evaluation of in-hospital counselling for first time myocardial infarction men. J Psychosom Res 1990; 34: 237-48.
74. Trzcieniecka-Green A, Steptoe A. Stress management in cardiac patients: a preliminary study of the predictors of improvement in quality of life. J Psychosom Res 1994; 38: 267-80.
75. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis. Arch Intern Med 1996; 156: 745-52.
76. Glassman AAH, Bigger JT Jr. Cardiovascular effects of therapeutic doses os tricyclic antidepressants: a review. Arch Gen Psychiatry 1981; 38: 815-20.
77. Glassman AH, Roose SP, Giardina EGV. Cardiovascular effects of tricyclic antidepressants. In: Meltzer HY, eds. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987: 1437-42.
78. Roose SP, Glassman AH. Antidepressant Choice in the Patient with Cardiac Disease: Lessons from the Cardiac Arrythmia Supression Trial (CAST) Studies. J Clin Psychiatry 1994; 55: 83-7.
79. Glassman AH, Johnson LL, Giardina EGV et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983; 250: 1997-2001.
80. Glassman AH. The newer antidepressant drugs and their cardiovascular effects. Psychopharm Bull 1984; 20: 272-9.
81. Ray WA, Griffin MR, Schaeffner W, et al. Psychotropic drugs usse and the risk of hip fracture. N Engl J Med 1987; 316: 363-9.
82. Glassman AH, Bigger JT Jr, Giardina EGV, et al. Clinical characteristics of imipramine-induced osthostatic hypotension. Lancet 1979; 1: 468-72.
83. Thayssen P, Bjerre M, Kragh-Sprensen P, et al. Cardiovascular effects of imipramine and nortriptyline in elderly. Psychopharmacol 1981; 74: 360-4.
84. Cardiac Arrhytmia Supression Trial (CAST) Investigators. Preliminary reports: effect of encainide and flecainide on mortality in a randomized trial of arrythmia supression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
85. Cardiac Arrhytmia Supression Trial II Investigators (CAST II). Effect of the antiarrhytmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-33.
86. Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhi-bitors for depression in patients with coronary heart disease? Am J Med 1997; 102: 54-9.
87. Cooper GL. The safety of fluoxetine: an update. Br J Psychiatry 1988; 153(suppl3): 77-86.
88. Kuhs H, Rudolf GAE. Cardiovascular effects of paroxetine. Psychopharmacol 1990; 102: 379-82.
89. Crewe HK, Leonard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochromc P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5.
90. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311-20.
91. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324: 641-8.
92. McFadden EP, Clarcke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324: 648-54.
93. Stokes PE. Fluoxetine: a 5-year Review. Clin Ther 1993; 15: 216-43.
94. Dunbar GC, Cohn JB, Fahre LF, et al. A Comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991; 159: 394-8.
95. Reimherr FW, Chouinard G, Cohn CK, et al. Antidepressant Efficacy of Sertraline: a Double-bind, Placebo and Amitriplyline-controlled Multicenter Comparison Study in Outpatients with Major Depression. J Clin Psychiatry 1990; 51 (suppl B): 18-27.
96. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735-9.
97. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287-91.
98. Roose SP, Dalack GW, Glassman AH, et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148: 512-6.
99. Khan A, Fabre LF, Rudolph R. Venlafaxine in depressed outpatients. Psychopharmacol Bull 1991; 27: 141-4.
100. Anon. Venlafaxine: a new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993; 54: 119-26.
101. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depression disorder. Psychopharmacol Bull 1990; 26: 191-6.
102. Vitullo RN, Wharton JM, Allen NB, Pritchet EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. CHEST 1990; 98: 247-8.
103. a ed. Boston: Little, Brown and Company 1995; pp81.
104. Lasnier C, Marey C, Lapeyreg G, Delalleau B, Ganry H. 4 Cardiovascular acceptability of tianeptine. Presse Med 1991; 20: 1858-63.
105. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976; 33: 1029-37.